Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Research & Development (2016 - 2025)

Historic Research & Development for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to $2.4 million.

  • Gyre Therapeutics' Research & Development fell 1484.68% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 221.27%. This contributed to the annual value of $12.0 million for FY2024, which is 1274.31% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Research & Development of $2.4 million as of Q3 2025, which was down 1484.68% from $3.4 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Research & Development high stood at $20.4 million for Q3 2021, and its period low was $803000.0 during Q3 2022.
  • Its 5-year average for Research & Development is $6.3 million, with a median of $3.4 million in 2025.
  • Per our database at Business Quant, Gyre Therapeutics' Research & Development crashed by 9605.44% in 2022 and then skyrocketed by 27471.98% in 2023.
  • Gyre Therapeutics' Research & Development (Quarter) stood at $16.1 million in 2021, then plummeted by 73.29% to $4.3 million in 2022, then increased by 6.01% to $4.6 million in 2023, then dropped by 18.74% to $3.7 million in 2024, then crashed by 36.34% to $2.4 million in 2025.
  • Its Research & Development was $2.4 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.1 million in Q1 2025.